Aldeyra Therapeutics/ALDX

$4.11

-2.61%
-
1D1W1MYTD1YMAX

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of primary vitreoretinal lymphoma, proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its ADX-246 and ADX-248, for geographic atrophy and systemic inflammatory diseases.

Ticker

ALDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Brady

Employees

15

Headquarters

Lexington, United States

ALDX Metrics

BasicAdvanced
$248.23M
Market cap
-
P/E ratio
-$0.78
EPS
1.51
Beta
-
Dividend rate

What the Analysts think about ALDX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
118.98% upside
High $11.00
Low $7.00
$4.11
Current price
$9.00
Average price target

ALDX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-8.1M
-8.99%
Profit margin
0%
-

ALDX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 41.28%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.22
-$0.27
-$0.15
-$0.14
-
Expected
-$0.31
-$0.29
-$0.31
-$0.24
-$0.14
Surprise
-29.74%
-7.4%
-51.75%
-41.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Aldeyra Therapeutics stock

Buy or sell Aldeyra Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing